Table 1 Demographic data of study participants stratified by haptoglobin (HP) phenotypes.
From: Haptoglobin polymorphism and prostate cancer mortality
Hp1-1 | Hp1-2 | Hp2-2 | p | |
|---|---|---|---|---|
n | 76 | 314 | 300 | |
Age at diagnosis (years) | 67.7 ± 6.8 | 68.6 ± 7.0 | 67.8 ± 7.2 | 0.31 |
Stage | ||||
T1/T2 | 36 (50.7) | 161 (56.7) | 151 (54.9) | 0.66 |
T3/T4 | 35 (49.3) | 123 (43.3) | 124 (45.1) | |
Gleason score | ||||
< 7 | 47 (61.8) | 192 (61.3) | 175 (58.3) | 0.71 |
≥ 7 | 29 (38.2) | 121 (38.7) | 125 (41.7) | |
PSA at diagnosis | ||||
< 10 | 31 (42.5) | 170 (56.5) | 162 (56.6) | 0.16 |
10–20 | 22 (30.1) | 75 (24.9) | 62 (21.7) | |
> 20 | 20 (27.4) | 56 (18.6) | 62 (21.7) | |
Risk group | ||||
Low | 10 (13.2) | 61 (19.4) | 64 (21.3) | 0.43 |
Intermediate | 21 (27.6) | 87 (27.7) | 70 (23.6) | |
High | 45 (59.2) | 166 (52.9) | 166 (53.3) | |
Death during follow-up | 21 (27.6) | 110 (35.0) | 120 (40.0) | 0.108 |
